STUDY OF ANTIFIBROTIC ACTIVITY OF MODIFIED AND NATIVE HYALURONIDASE AT PULMONARY FIBROSIS
Author Affiliations1Goldberg Research Institute of Pharmacology and Regenerative Medicine
2Goldberg Research Institute of Pharmacology and Regenerative Medicine
3Goldberg Research Institute of Pharmacology and Regenerative Medicine
4Goldberg Research Institute of Pharmacology and Regenerative Medicine
5Goldberg Research Institute of Pharmacology and Regenerative Medicine
6Novosibirsk State Medical University of Minzdrav of Russia
7Novosibirsk State Medical University of Minzdrav of Russia
8Novosibirsk State Medical University of Minzdrav of Russia
9Goldberg Research Institute of Pharmacology and Regenerative Medicine
Abstract
This study of the antifibrotic activity of poloxamer-modified and native hyaluronidase was conducted using the model of partial reversible pulmonary fibrosis caused by one-time administration of bleomycine. The preparations were administered in the intranasal preventive and therapeutic modes. It has been established that modified hyaluronidase when used in the therapeutic mode has more pronounced antifibrotic action in comparison to native enzyme. When administered in the preventive mode, modified hyaluronidase prevents the development of pulmonary fibrosis.
Key words
References
- Avdeev S.N. Idiopathic pulmonary fibrosis: current approaches to therapy // Prakticheskaya pul'monologiya = Practical pulmonology. 2015. (1). 22–31. [In Russian].
- Dygay A.M., Skurikhin E.G., Ermakova N.N. et al. Antifibrotic effects of immobilized hyaluronidase in repeated bleomycin-induced lesions of the alveolar epithelium // Bul. Exp. Biol. Med. 2013. 155. (4). 501–506.
- Dygai A.M., Skurikhin E.G., Pershina O.V. et al. Stem and progenitor cells in the pathogenesis of pulmonary fibrosis // Patogenez = Pathogenesis. 2013. (1) 36–51. [In Russian].
- Dygai A.M., Skurikhin E.G., Khmelevskaya E.S. et al. Effect of immobilized hyaluronidase on steam and progenitor cells in pulmonary fibrosis // Bul. Exp. Biol. Med. 2014. 156. (4). 590–594.
- Madonov P.G., Ershov K.I., Dubrovin A.V. et al. Electron-beam modification of preparations of the albuminous nature for improvement of their pharmacological properties. // Meditsina i obrazovanie v Sibiri = Medicine and Education in Siberia. 2013. (4). http://www.ngmu.ru/cozo/mos/article/pdf.php?id=1115. [In Russian].
- Patent 2497523 RF. A method for increasing the efficiency of therapy of disturbances in lung tissue during cytostatic treatment / Madonov P.G., Yermakova N.N., Reztsova A.M. et al.; published 08.07.2013. [In Russian].
- Skurikhin E.G., Pershina O.V., Krupin V.A. et al. Effects and mechanisms of pegylated hyaluronidaze in C57BL/6 mice under bleomycin induced pulmonary fibrosis // Patogenez = Pathogenesis. 2015. (3). 56–64. [In Russian].
- Skurikhin E.G., Reztsova A.M., Ermakova N.N. et al. Antifibrotic activity of conjugates based on amphiphilic pluronic F68 and hydrophobic pluronic L31 with hyaluronate-endo-β-N-acetylhexosaminidase in pulmonary fibrosis // Bul. Exp. Biol. Med. 2014. 157. (1). 5–9.
- Kwiecien M., Homa M., Budasz-Swiderska M. et al. Idiopathic pulmonary fibrosis as a challenge for the Polish healthcare system // J. Health Policy Outcomes Res. 2015. (2). 6–17.
- Troy L.K. Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses // Eur. Respir. J. 2016. 47. (1). 27–30.
- Woodcock H.V., Maher T.M. The treatment of idiopathic pulmonary fibrosis // F1000Prime Rep. 2014. 6. ID 16. http://f1000.com/prime/reports/m/6/16
About Authors (Correspondence):
Madonov P.G. – doctor of medical sciences, professor, head of the chair for pharmacology, clinical pharmacology and evidentiary medicine, e-mail:madonov@scpb.ru
Full Text